All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Travoprost
Therapeutic Area: Ophthalmology Product Name: iDose TR
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 13, 2021
Details:
iDose® TR sustained-release travoprost implant continued to provide sustained substantial reductions in intraocular pressure (IOP) in a 24-month interim analysis of the ongoing 36-month Phase 2b clinical trial conducted under a U.S. Investigational New Drug (IND) protocol.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Phentolamine
Therapeutic Area: Ophthalmology Product Name: Nyxol
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 06, 2021
Details:
The current study builds on the positive results achieved in Ocuphire's recent Phase 2b MIRA-1 trial, which provided evidence of Nyxol’s ability to more rapidly return pupil diameter back to normal baselines.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Tropicamide,Phenylephrine Hydrochloride
Therapeutic Area: Ophthalmology Product Name: MydCombi
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 29, 2020
Details:
The NDA submission follows the initial enrollment of the VISION-1 study, Eyenovia’s Phase 3 study for MicroLine in presbyopia, with top-line data expected the first half of 2021.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Varenicline Tartrate
Therapeutic Area: Ophthalmology Product Name: OC-01
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 18, 2020
Details:
The NDA submission for OC-01, is based on efficacy and safety results from a comprehensive clinical trial program conducted in patients with a broad range of dry eye disease.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Phentolamine
Therapeutic Area: Ophthalmology Product Name: Nyxol
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Oculos Development Services
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 19, 2020
Details:
Nyxol, a stable eye drop formulation of phentolamine mesylate, has been shown to reverse mydriasis in a recently completed Phase 2b clinical trial (MIRA-1). MIRA-2 trials are to evaluate the efficacy and safety of Nyxol vs commonly used mydriatic (dilating) drops.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Phentolamine
Therapeutic Area: Ophthalmology Product Name: Nyxol
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: National Institutes of Health
Deal Size: $1.7 million Upfront Cash: Undisclosed
Deal Type: Funding November 16, 2020
Details:
Ocuphire Pharma received grant from the National Eye Institute (NEI) to continue studies on APX3330, as well as second generation compounds, APX2009 and APX2014. It also received Japanese Patent for daily ophthalmic use of nyxol to Improve Visual Performance.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Tanfanercept
Therapeutic Area: Ophthalmology Product Name: HBM9036
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 16, 2020
Details:
The proof-of-concept study demonstrated efficacy, safety, and tolerability of Tanfanercept for the treatment of moderate-to-severe dry eye disease (DED) in China.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
